Loading
Chaired the COG leukaemia committee through the era that pushed childhood ALL cure rates above 90%.
Stephen Hunger chaired the Children's Oncology Group acute lymphoblastic leukaemia committee from 2008 to 2016 and led the analyses documenting improved survival across successive trials, the Ph-like ALL discovery work with Charles Mullighan, and the trials that added imatinib to chemotherapy for Philadelphia-positive ALL. He co-authored the NEJM review of childhood ALL and leads oncology at CHOP.
Shares COG AALL1731, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, Acute lymphoblastic leukaemia and the tags paediatric, all.
Shares COG AALL1731, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, Acute lymphoblastic leukaemia.
Shares Blinatumomab, Acute lymphoblastic leukaemia and the tags all, cooperative-group.
Shares COG AALL1731, Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL, Blinatumomab, Acute lymphoblastic leukaemia.
Shares the tags paediatric, cooperative-group.
Shares Acute lymphoblastic leukaemia and the tags paediatric, all.
Shares Blinatumomab, Imatinib, Acute lymphoblastic leukaemia and the tag cooperative-group.
Shares the tags paediatric, cooperative-group.